Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Phylogica — Shareholder Meeting (November 2011)
39 slides from Pyc Therapeutics's shareholder meeting presentation, Nov 24, 2011
Slide 1: Harnessing Biodiversity for Peptide Therapies
For personal use only Phylogica Harnessing Biodiversity for Peptide Therapies Annual General Meeting 24 November 2011 1 Thursday, 24 November 2011
Slide 2: Contents
For personal use only Contents Introduction Dr Paul Watt, CEO Operational review Dr Paul Watt, CEO Technology review Dr Paul Watt, CEO Phylomer validation data Dr Richard Hopkins, COO & VP Research Financial review Mr Nick Woolf, CFO & VP Corporate Development 2 Thursday, 24 November 2011
Slide 3: Introduction
Introduction Biotech company offering leading peptide drug discovery services For personal use only Based in Perth, Western Australia, and Oxford, UK Headcount of approx. 25 employees Assembled world class peptide drug discovery platform Based on world’s most structurally diverse library of natural
Slide 4: Investment Highlights
Investment Highlights Strategy for rapid revenue growth from fee-for-service alliances For personal use only Since 2009, signed partnerships with Roche, AstraZeneca & Pfizer Positioned for cash flow sustainability in 2012/2013 Key Numbers 10 billion peptides in our proprietary libraries 3 partnershi
Slide 5: Experienced Management Team
Experienced Management Team Dr Douglas Wilson - Executive Chairman • Former Senior Vice-President, Medicine for Boehringer Ingelheim For personal use only • Overseen multiple drugs at all phases of development • Overseen many drugs successfully to the market in the USA Dr Paul Watt – CEO • Commonwea
Slide 6: Operational Review
Operational Review For personal use only Building a Sustainable Discovery Alliance Business 6 Thursday, 24 November 2011
Slide 7: Focus on Drug Discovery Reduces Risk
Focus on Drug Discovery Reduces Risk Discovery Humans For personal use only Phylogica Co-development/Partner Humans Co-development path Upfront fees and research funding provide immediate revenue stream Build long-term value through milestones and royalties Secure increasing share of down-stream val
Slide 8: Partnerships with Three Top-10 Pharma
Partnerships with Three Top-10 Pharma Roche For personal use only • Collaboration to discover cell-penetrating peptides in December 2009 • Successful completion of initial research objectives in February 2011 • Expanded to discover peptides that cross blood-brain barrier in May 2011 MedImmune (Astra
Slide 9: 'Target Discovery' Collaboration with Cambridge
‘Target Discovery’ Collaboration with Cambridge For personal use only Successful collaboration with Cambridge University to develop new application of Phylomers as probes to identify disease-associated drug targets Support from Cambridge Enterprise to spin-out new company ‘Phenomica’ to commercialis
Slide 10: Technology Review
Technology Review For personal use only Phylomers: Unique Source of Bioactive “Peptides” 10 Thursday, 24 November 2011
Slide 11: Advantages of Peptides vs. Other Biologic Classes
Advantages of Peptides vs. Other Biologic Classes Peptides (protein fragments) have advantages over larger biologics For personal use only • can be delivered by more patient friendly routes – eg: intranasal • can be made synthetically at low cost • can penetrate cells and access intracellular target
Slide 12: Rapid Growth in Peptide Drug Market
Rapid Growth in Peptide Drug Market Peptides are one of the fastest growing For personal use only drug classes • 60 marketed peptides represent $13 billion market • Peptide market growing twice as fast as small molecules • New technologies have addressed traditional challenges for peptide Chemical &
Slide 13: Demand for Novel Approaches to Peptide Drug Discovery
For personal use only Demand for Novel Approaches to Peptide Drug Discovery Guess peptide sequence from random combinatorial libraries (eg. Affymax) Design peptide inhibitors that mimic known natural interfaces (eg. Kai, Aileron, Trimeris) Find new structures within proteins which have already been
Slide 14: Phylomers Derive from Parts of Biodiverse Proteins
Phylomers Derive from Parts of Biodiverse Proteins Encoded from >35 biodiverse bacterial genomes, environments like For personal use only volcanic streams, geysers and deep sea vents Phylomer libraries contain several billion distinct peptides Pre-selected by evolution to allow survival, such as the
Slide 15: Bacteria Provide Richest Source of Diversity
Bacteria Provide Richest Source of Diversity World’s richest source of structurally diverse natural peptides For personal use only Watt PM (2006) Nature Biotechnology Vol 24 (2):177-83 15 Thursday, 24 November 2011
Slide 16: Phylomers Derive from Multiple Structural Families
Diversity: Phylomers Derive from Multiple Structural Families Bacteroides: (40L_0859) Bordetella: (40L_0716) Haloarcula: (40L_0735) For personal use only Homologous Crystal Structure S. enterica. E. coli. B. stearothermophilus (dTDP-D-glucose 4,6-dehydratase) (Ferric siderophore receptor) (Alpha-L-a
Slide 17: Fully-Integrated Drug Discovery Platform
Fully-Integrated Drug Discovery Platform Phylomer Rapid Hit-to-Lead Lead Drug Candidate For personal use only Libraries Screening Conversion Optimisation Enhancement Multiple formats Proprietary high- Core expertise in Technologies for Technology to depending on throughput functional analysis matura
Slide 18: Harvesting Structural Diversity for Drug Discovery
For personal use only Harvesting Structural Diversity for Drug Discovery Watt 2009 Future Medicinal Chemistry. 1 (2) 257-265. 18 Thursday, 24 November 2011
Slide 19: Phylomers: A Powerful Toolbox for Drug Discovery
For personal use only Phylomers: A Powerful Toolbox for Drug Discovery Intracellular Targets Extracellular Targets Phenotypic Phylomers Antimicrobial Screening Epitope Mapping Scaffold Discovery Cell Penetrating Peptides 19 Thursday, 24 November 2011
Slide 20: Phylomer Libraries: a rich source of novel cell penetrating peptides
For personal use only Phylomer Libraries: a rich source of novel cell penetrating peptides Thursday, 24 November 2011
Slide 21: Roche project: crossing the blood brain barrier
For personal use only Roche project: crossing the blood brain barrier Cell penetrating peptide Thursday, 24 November 2011
Slide 22: Cell penetrating Phylomers - expanding the druggable landscape
Cell penetrating Phylomers - expanding the druggable landscape Druggable landscape consists of; For personal use only Extracellular targets (10%) • targeted by antibodies, recombinant proteins, peptides (biologics) Intracellular targets (90%) • Small Molecule Drugs (10%) • Currently inaccessible to
Slide 23: Three cell penetrating (CPP) selections strategies
Three cell penetrating (CPP) selections strategies CHO For personal use only Phylomer libraries Direct selection T7 M13 bEnd.3 Negative selection Positive selection Phylomer libraries Cell-directed selection T7 M13 bEnd.3 Phylomer libraries Cell binding selection T7 M13 bEnd.3 Thursday, 24 November
Slide 24: Summary of CPP and cell binding selections
For personal use only Summary of CPP and cell binding selections Clone number Unique sequences (n) 992 Peptides synthesised 153 (15%) Recombinant peptides 13 (1%) FACS +ve (Bend.3/CHO) 46 (30%) Microscopy +ve (Bend.3/CHO) 17 (11%) Thursday, 24 November 2011
Slide 25: Bioinformatic analysis of unique sequence
Bioinformatic analysis of 992 unique sequence 2-fold enrichment for classical CPP-like sequences (~14%) For personal use only • classical TAT-like amphipathic, cationic peptides - positively charged • bind to cell membranes via electrostatic interaction which facilitates cell-uptake • binding mechan
Slide 26: Bioinformatic analysis of unique sequence
Bioinformatic analysis of 992 unique sequence 2-fold enrichment for classical CPP-like sequences (~14%) For personal use only • classical TAT-like amphipathic, cationic peptides • most Phylomers could not be assigned to previous characterised CPP families Many Phylomers derived from membrane-associa
Slide 27: Confocal microscopy confirms Phylomer CPP activity
For personal use only Confocal microscopy confirms Phylomer CPP activity CPP Phylomer -ve Control (5 µM) FITC-BEN_0398 FITC-BEN_0540 FITC- BEN_1079 PYC 38-TAT (5 µM) 5 µM 5 µM 5 µM Fixed Cells Thursday, 24 November 2011
Slide 28: Multiple classes of validated Phylomer CPPs
For personal use only Multiple classes of validated Phylomer CPPs Length Phylomer Comments Charge (aa) • Arginine rich TAT-like sequence. BEN_1079 18 +9 • RCGRASRCRVRWMRRRRI • Similar to gp41 transmembrane protein from SIV. BEN_0805 • Facilitates fusion between viral and endosomal membranes. 26 +3 •
Slide 29: Summary: cell penetrating Phylomer screen
For personal use only Summary: cell penetrating Phylomer screen Phylomer libraries represent a rich source of novel cell penetrating peptides. Identified different classes of cell penetrating peptide Nature has already solved the problem of cell entry! Next generation Phylomer libraries will include
Slide 30: Key Advantages of Phylomers
Key Advantages of Phylomers Highly flexible drug discovery platform For personal use only • Antimicrobial peptides (Astrazeneca/MedImmune) • Vaccines (Pfizer) Provide access for biologics to intracellular targets. • Novel source of cell penetrating peptides for delivery of therapeutic cargoes • Prov
Slide 31: Thanks to the Phylogica Team
For personal use only Thanks to the Phylogica Team Thursday, 24 November 2011
Slide 32: Financial Review: Delivering on Strategy
Financial Review For personal use only Delivering on Strategy 32 Thursday, 24 November 2011
Slide 33: Objective to Add Three New Partnerships in FY2012
Objective to Add Three New Partnerships in FY2012 Rank Company Signed Activity Value For personal use only 1 Johnson & Johnson 2 Pfizer 2010 Therapeutic peptide vaccines >US$134M 3 Roche 2009 Cell-penetrating & blood-brain delivery NA 4 GlaxoSmithKline 5 Novartis 6 Sanofi-Aventis 7 AstraZeneca (MedI
Slide 34: Leveraging Discovery Alliances to Build Value
For personal use only Leveraging Discovery Alliances to Build Value Potential Revenue (Cumulative) $1000m $750m $500m $250m $0m 2009 2010 2011 2012 34 Thursday, 24 November 2011
Slide 35: Robust Finances Supported by Revenue
For personal use only Robust Finances Supported by Revenue FY2011 results in line with expectations • Revenue of A$2.5 million (+259% vs. FY2010) • Net loss narrowed to A$3.6 million (vs. A$4.6 million) Analysts estimate +100% revenue growth in FY2012 Net cash of A$3.3 million at 30 September 2011 P
Slide 36: Major Shareholders
For personal use only Major Shareholders NAOS Asset Management: 11% Australian Heritage Group: 8% Ascent BioMedical Holdings: 5% Telethon Institute of Child Health Research: 5% Management: 5% 36 Thursday, 24 November 2011
Slide 37: One-Year Share Price Performance (PYC.AX)
es 1.86% INVESTING One-Year Share Price Performance (PYC.AX) NEWS & OPINION MY PORTFOLIOS PERSONAL FINANCE SMALL BUSINESS VIDEO GET QUOTES Wed 23 Nov 2011 18:21 - Australia Markets closed Issued capital of 405 million shares a Limited (PYC.AX) For personal use only 16:10: 0.05 0.00 (0.00%) .AX Share
Slide 38: Summary
For personal use only Summary Assembled world-class peptide drug discovery platform Successfully validated ‘Alliance Model’ with three pharma partners Strong institutional shareholder base Anticipate rapid revenue growth based on current and prospective deals Objective to close at least three new ma
Slide 39: For personal use only
Dr. Paul Watt Nick Woolf Chief Executive Officer For personal use only CFO, VP Corporate Development Tel: +61 8 9382 8888 Tel: +61 8 9382 8888 Fax: +61 8 9382 1766 Fax: +61 8 9382 1766 Mobile UK: +44 7775 682478 Mobile AUS: +61 417 986 005 paulw@phylogica.com nwoolf@phylogica.com 39 www.phylogica.co